UY33305A - Compuestos heterocíclicos inhibidores de DGAT1 - Google Patents

Compuestos heterocíclicos inhibidores de DGAT1

Info

Publication number
UY33305A
UY33305A UY0001033305A UY33305A UY33305A UY 33305 A UY33305 A UY 33305A UY 0001033305 A UY0001033305 A UY 0001033305A UY 33305 A UY33305 A UY 33305A UY 33305 A UY33305 A UY 33305A
Authority
UY
Uruguay
Prior art keywords
heterocyclic compounds
compounds inhibiting
inhibiting dgat1
dgat1
prodrugs
Prior art date
Application number
UY0001033305A
Other languages
English (en)
Inventor
Alan Martin Birch
Leach Andrew
Frederick Woolf Goldberg
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY33305A publication Critical patent/UY33305A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

Se describen compuestos inhibidores de DGAT1 de fórmula (I), sales y profármacos farmacéuticamente aceptables de estos, junto con composiciones farmacéuticas, procedimientos para hacerlos y su uso en el tratamiento por ejemplo de la diabetes y la obesidad.
UY0001033305A 2010-04-01 2011-03-31 Compuestos heterocíclicos inhibidores de DGAT1 UY33305A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31994610P 2010-04-01 2010-04-01
US36804010P 2010-07-27 2010-07-27

Publications (1)

Publication Number Publication Date
UY33305A true UY33305A (es) 2011-10-31

Family

ID=44023074

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033305A UY33305A (es) 2010-04-01 2011-03-31 Compuestos heterocíclicos inhibidores de DGAT1

Country Status (4)

Country Link
US (1) US20110251173A1 (es)
TW (1) TW201136941A (es)
UY (1) UY33305A (es)
WO (1) WO2011121350A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ630436A (en) * 2012-11-23 2016-08-26 Glaxosmithkline Llc Novel compounds as diacylglycerol acyltransferase inhibitors
US9796729B2 (en) 2012-11-23 2017-10-24 Glaxosmithkline Llc Compounds as diacylglycerol acyltransferase inhibitors
KR20150090100A (ko) 2012-12-03 2015-08-05 에프. 호프만-라 로슈 아게 스테아로일-CoA 불포화화효소 1(에스씨디 1)의 억제제로서의 치환된 이속사졸 아마이드 화합물
CN104418866B (zh) 2013-08-23 2018-10-16 青岛黄海制药有限责任公司 Dgat1抑制剂及其制备方法和用途
BR112019012300A2 (pt) * 2016-12-15 2019-11-12 Glaxosmithkline Ip Dev Ltd ativadores nrf2
AR111776A1 (es) * 2017-05-11 2019-08-21 Astrazeneca Ab Heteroarilos inhibidores de las proteínas ras mutantes de g12c

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0325192D0 (en) 2003-10-29 2003-12-03 Astrazeneca Ab Method of use
AU2005315430B2 (en) 2004-12-14 2010-05-27 Astrazeneca Ab Oxadiazole derivatives as DGAT inhibitors
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
KR20120037939A (ko) 2009-06-19 2012-04-20 아스트라제네카 아베 Ｄｇａｔ１의 억제제로서 피라진 카르복사미드

Also Published As

Publication number Publication date
WO2011121350A1 (en) 2011-10-06
TW201136941A (en) 2011-11-01
US20110251173A1 (en) 2011-10-13

Similar Documents

Publication Publication Date Title
DOP2012000006A (es) Agonista de gpr119
MX2019010602A (es) Inhibidores de cdk.
CL2009000426A1 (es) Compuestos derivados de carbociclil/heterociclil-piridin-2-il-urea, inhibidores de topoisomerasa iv bacteriana; composicion farmaceutica; y su uso para el tratamiento de infecciones bacterianas
CO6640270A2 (es) Morfolinopirimidad y su uso en terapia
CU20160149A7 (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
DOP2014000152A (es) Inhibidores de bromodominios
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
CR11518A (es) Compuestos de carbamoilo como inhibidores de dgat1 190
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
UA111744C2 (uk) ЗАМІЩЕНІ ПІРИДОПІРАЗИНИ ЯК ІНГІБІТОРИ Syk
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
CL2012000937A1 (es) Compuestos heterociclicos espiro derivados de ciclohexano, inhibidores de hsl; procedimiento de preparacion; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento de diabetes, sindrome metabolico, dislipidemia, aterosclerosis u obesidad.
MA33937B1 (fr) Composes pyrazole comme antagonistes du recepteur crth2
CL2012003681A1 (es) Compuestos derivados de piperidina; composicion farmaceutica; y su uso como inhibidores de acetil-coa carboxilasa para el tratamiento de trastornos metabolicos, tales como obesidad y diabetes.
NI201400042A (es) 2 - tiopirimidinonas
GT201500235A (es) Estra -1,3,5 (10) , 16- tetraeno -3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1c3)
UY33655A (es) Co-cristales y sales de inhibidores de ccr30
AR079945A1 (es) Derivados de pirazina como inhibidores de glucogeno sintasa quinasa 3 (gsk3)
CY1120133T1 (el) Πυριδαζινονες ως αναστολεις ενζυμου daao
UY33305A (es) Compuestos heterocíclicos inhibidores de DGAT1
UY32716A (es) Compuestos de pirazina carboxamida útiles para el tratamiento de diabetes y obesidad
EA201591175A1 (ru) Трициклические соединения в качестве ингибиторов cftr
EA201270728A1 (ru) Пуриновые соединения
UY32694A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20191218